Detroit, MINCT06420167Now EnrollingIRB Ready

Renal AL Amyloidosis Clinical Trial in Detroit, MI

Access cutting-edge renal al amyloidosis treatment through this clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Barbara Ann Karmanos Cancer Institute

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access renal al amyloidosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related renal al amyloidosis treatment provided free

Apply for This Detroit Location

Check if you qualify for this renal al amyloidosis clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Renal AL Amyloidosis Study in Detroit

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: * screened for the trial via an online platform * contacted by study personal to obtain electronic consent * enrolled in the trial if eligible and consented * contacted by study personal for further instructions and directions * sent dapagliflozin oral medication (supplied by the site pharmacy) * followed up regularly with the study team via telemedicine or other online avenues * monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months * continue treatment for 6 months

Sponsor: Barbara Ann Karmanos Cancer Institute

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form.
Stated willingness to comply with study procedures, including remote telehealth consultations with the study team, confirming availability, and agreeing to use mobile/web applications for study purposes.
Age ≥18 years.
Histopathologic diagnosis of renal AL amyloidosis confirmed by biopsy of any tissue and evidence of \>1.0 g/day proteinuria without any other identifiable cause.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
Plateau in any renal response (i.e., reduction in proteinuria) for at least 3 months prior to enrollment, as determined by the enrolling physician.
Residence in the state of Michigan.

Exclusion Criteria

Either ongoing first line induction with anti-plasma cell therapy or ongoing post- induction maintenance for \<6 months prior to enrollment.
Diagnosis of symptomatic multiple myeloma, including presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the bone marrow, or hypercalcemia, either currently or in the past.
Women of child-bearing potential (i.e., those who have not undergone chemical or surgical sterilization or are not postmenopausal) and who are unwilling to use a medically accepted and reliable form of contraception while participating in the study and for 2 weeks following the last dose of study medication, as determined by the investigator, or have a positive pregnancy test at the time of enrolment or are currently breastfeeding.
Known allergic reactions to components of the dapagliflozin.
Treatment requiring type 1 or type 2 diabetes mellitus.
Baseline eGFR \<25 mL/min/1.73m2.
Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices or coagulopathy)
Current or previous use of any SGLT2i.
Initiation or dose modification of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) \<3 months prior to enrollment.
Active malignancy requiring treatment (other than AL amyloidosis and non-melanoma skin cancers).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT06420167) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Renal AL Amyloidosis Treatment Options in Detroit, MI

If you're searching for renal al amyloidosis treatment options in Detroit, MI, this clinical trial (NCT06420167) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced renal al amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all renal al amyloidosis clinical trials near you to find additional studies recruiting in your area.

More Amyloidosis Trials in Detroit, MI

See all amyloidosis clinical trials recruiting in Detroit — not just this study.

Browse Amyloidosis Trials in Detroit →

Browse More Trials by Condition

Amyloidosis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI